BERNARDINO
ALCÁZAR NAVARRETE
PROFESOR PERMANENTE LABORAL
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublications in collaboration with researchers from GlaxoSmithKline (United Kingdom) (5)
2024
-
Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial
Archivos de Bronconeumologia, Vol. 60, Núm. 7, pp. 417-422
2018
-
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective
Respiratory Research, Vol. 19, Núm. 1
-
Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
Pulmonary Therapy, Vol. 4, Núm. 2, pp. 171-183
2017
-
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study
Advances in Therapy, Vol. 34, Núm. 11, pp. 2518-2533